Sportstech Announced Strong Results, with April 2025 revenue growth at 36% YOY
Current FX rates indicate that the LTM figures would be approximately $54M in Revenue and $5M in EBITDA through April 2025
Strong Business Momentum, Revenue and Positive EBITDA Underscore Target's Operational Strength and Logic of Acquisition in advance of Closing
Read More
DEA's Diversion Control Division leadership implicated in the obstruction of MMJ 's DEA registration and delays in cannabis-based pharmaceutical research are Thomas W. Prevoznik, Matthew Strait and DEA Administrative Law Judges (ALJs) all who under the agency's control, raising serious concerns about due process, impartiality, and accountability.
Read More
N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
eXoZymes used its AI-driven development platform to progress from idea to purpose-built subsidiary in less than 3 months and at a fraction of normal SynBio R&D cost.
NCTx is scaling up an exozyme biosolution to overcome a longstanding bottleneck in sourcing the NCT compound from nature, where it occurs only in trace amounts.
Interesting pre-clinical data point towards Non-Alcoholic Fatty Liver Disease (NAFLD) that affects more than 30% of the global population.
Only NCTx can make both the natural product NCT, and a range of very interesting new-to-nature analog versions, expanding the pharma potential.
NCT is the first of more "powered by eXoZymes" natural product nutraceuticals, that also have the potential to become pharmaceuticals.
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st
Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO
Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD Meeting in March; data from adolescent subset presented at World Congress of Pediatric Dermatology in April
Positive top line results from icotrokinra Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) announced in March, data to be presented at medical conference later in 2025
Cash, cash equivalents and marketable securities of $697.9 million as of March 31, 2025, anticipated to provide cash runway through at least end of 2028
Read More
Addison Care delivers the industry's most comprehensive AI-enabled chronic care platform - offering vitals monitoring, automated wellness checks, caregiver support, and integrated TeleCare services - now accessible to thousands of clinics through Athenahealth's nationwide EHR ecosystem.
Read More
Nerva, the world's leading digital therapeutic for Irritable Bowel Syndrome (IBS), announced today that it has acquired key assets of Mahana Therapeutics, a pioneer in digital therapies for chronic conditions, including IBS.
Read MorePreclinical data supports the advancement of oral Ketamir-2 as a safe, next-generation alternative to ketamine, with ongoing momentum in Phase I clinical trial enrollment
Read More
With six newly established, identical BSL-2 laboratories now operational, biologics CDMO Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks
Read More
Message to President Trump's Appointee: Terrance Cole Must Act on Cannabis Scientific Reform.
"Mr. Cole has a historic opportunity to lead with integrity, science, and constitutional fidelity," said Boise. "He must put an end to this unlawful administrative hearing, root out DEA institutional marijuana bias, and restore lawful science-based regulatory practices."
Read MoreCompassion Center announces a dynamic giveaway contest, offering two exclusive tickets to Psychedelic Science 2025. Participants can win by maximizing social media shares or submitting compelling personal statements. Contestants must engage with Compassion Center's social channels, with winners announced on May 25, ahead of the prestigious June conference.
Read More
The developer of sustained acoustic medicine technology and the sam® wearable ultrasound device and number one resource for arthritis information will support the Foundation's efforts to provide resources and education to patients, families and caregivers.
Read More
This agreement will introduce a new technology that has already demonstrated strong results in promoting wound healing to the United States.
Read More
FibroMAP combines the power of high-resolution, single-fiber, and spatially resolved datasets generated by PharmaNest's digital pathology and image analysis platform (FibroNest) with advanced clustering techniques such as Uniform Manifold Approximation and Projection (UMAP) to interpret complex, high-dimensional data. FibroMAP is poised to revolutionize the study of fibrosis histology in the same way that single-cell analysis transformed biology.
Read MoreEach ID combines the lifesaving simplicity of custom engraving with the power of a scannable QR code, giving wearers instant access to their full online health record when it matters most.
Read MoreAcquisitions are On Track and Progressing From Signing to Closing; Guidance of $65M+ In Pro Forma Revenues Remains In Place
TRNR Expects to Provide Positive Update on Sportstech Q1 2025 Performance in May 2025
Read MoreReports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52)
Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billion
Announces reduction of $1.4 to $1.7 billion in estimated GAAP operating costs by 2027
Advancing up to 10 products toward approval, including multiple oncology candidates
Read More
Mentavi, a national leader in online mental health testing, will attend the 10th World Congress on ADHD and present a first-ever study comparing the accuracy and validity of an online asynchronous assessment for diagnosing ADHD in adults with the current standard of care, a clinical interview.
Read More“We are not just challenging DEA policy, we are defending the Constitution said Duane Boise, CEO of MMJ BioPharma Cultivation. The DEA cannot sidestep Supreme Court precedent and force us into a hearing. The agency is running a closed loop of power, Boise added, they investigate, prosecute, judge and override all in-house. That’s not justice, that’s a rigged game.”
Read MoreCompany Confirms Both Acquisitions are On Track and Progressing From Signing to Closing, Reiterates Guidance of $65M+ Pro Forma Revenues
TRNR to Provide Positive Update on Sporstech Q1 2025 Performance in May 2025
Read More
